HOOKIPA PHARMA INC. Forms 3, 4 and 5: Stock Options
Statements of beneficial ownership filed with the SEC by officers, directors and 10% owners: 18 rows in 2021. Transaction codes are the SEC's. Shares and prices are split-adjusted; the as-filed figure is underneath.
- 2021-12-21: Reporting owner Matushansky Igor; Form 4; Security Stock Option (Right to Buy); Transaction M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3.
- 2021-12-21: Reporting owner Matushansky Igor; Form 4; Security Stock Option (Right to Buy); Transaction M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3.
- 2021-12-21: Reporting owner Matushansky Igor; Form 4; Security Stock Option (Right to Buy); Transaction M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3.
- 2021-06-01: Reporting owner van de Winkel Jan; Form 4; Security Stock Option (Right to Buy); Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
| Transaction date | Reporting owner | Form | Security | Transaction | Shares | Price | Price that day | Filing |
|---|---|---|---|---|---|---|---|---|
| 2021-12-21 | Matushansky Igor Officer (Chief Medical Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −8,079 0 owned after | $0.10 exercise price | 2022-01-12 | |
| 2021-12-21 | Matushansky Igor Officer (Chief Medical Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −11,366 2,842 owned after | $0.10 exercise price | 2022-01-12 | |
| 2021-12-21 | Matushansky Igor Officer (Chief Medical Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −3,408 4,261 owned after | $0.10 exercise price | 2022-01-12 | |
| 2021-06-01 | van de Winkel Jan Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +19,200 19,200 owned after | $16.61 exercise price | 2021-06-04 | |
| 2021-06-01 | Soria Jean-Charles Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +9,600 9,600 owned after | $16.61 exercise price | 2021-06-04 | |
| 2021-06-01 | Seghezzi Graziano Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +9,600 9,600 owned after | $16.61 exercise price | 2021-06-04 | |
| 2021-06-01 | O'Neill Julie Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +9,600 9,600 owned after | $16.61 exercise price | 2021-06-04 | |
| 2021-06-01 | Lengauer Christoph Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +9,600 9,600 owned after | $16.61 exercise price | 2021-06-04 | |
| 2021-06-01 | Kelly Michael Aaron Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +9,600 9,600 owned after | $16.61 exercise price | 2021-06-04 | |
| 2021-06-01 | Kaufman David Ross Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +9,600 9,600 owned after | $16.61 exercise price | 2021-06-04 | |
| 2021-04-19 | Necina Roman Officer (Chief Technology Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +36,750 36,750 owned after | $12.00 exercise price | 2021-04-21 | |
| 2021-04-19 | Orlinger Klaus Officer (Sr. VP, Research) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +26,050 26,050 owned after | $12.00 exercise price | 2021-04-21 | |
| 2021-04-19 | Baker Christine D. Officer (Chief Business Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +49,950 49,950 owned after | $12.00 exercise price | 2021-04-21 | |
| 2021-04-19 | Matushansky Igor Officer (Chief Medical Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +95,250 95,250 owned after | $12.00 exercise price | 2021-04-21 | |
| 2021-04-19 | Kandera Reinhard Officer (Chief Financial Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +69,300 69,300 owned after | $12.00 exercise price | 2021-04-21 | |
| 2021-04-19 | Aldag Jorn Director, Officer (Chief Executive Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +207,600 207,600 owned after | $12.00 exercise price | 2021-04-21 | |
| 2021-03-22 holding as of filing | Baker Christine D. Officer (Chief Business Officer) | 3 | Stock Option (Right to Buy) Derivative · Direct | Holding | $8.21 exercise price | 2021-03-22 | ||
| 2021-03-22 holding as of filing | Baker Christine D. Officer (Chief Business Officer) | 3 | Stock Option (Right to Buy) Derivative · Direct | Holding | $8.03 exercise price | 2021-03-22 |